XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Income Statement [Abstract]        
Revenues $ 762.1 $ 667.6 $ 1,479.5 $ 1,333.8
Operating expenses:        
Salaries and benefits 223.2 195.2 438.4 397.4
Supplies 199.7 182.2 388.5 370.6
Professional and medical fees 92.4 72.9 175.0 147.5
Lease expense 22.2 21.8 43.6 43.2
Other operating expenses 45.4 41.4 99.5 87.0
Cost of revenues 582.9 513.5 1,145.0 1,045.7
General and administrative expenses 40.3 31.2 73.5 63.2
Depreciation and amortization 34.8 24.4 68.5 58.1
Transaction and integration costs 19.3 12.0 36.7 24.5
Net loss (gain) on disposals, consolidations and deconsolidations 5.3 (8.8) 6.8 1.7
Equity in earnings of unconsolidated affiliates (4.4) (2.6) (7.1) (5.9)
Litigation settlements 0.5 1.5 (1.3) 4.5
Loss on debt extinguishment 5.1 0.0 5.1 0.0
Other income, net (6.5) (1.2) (8.5) (2.0)
Total operating expenses 677.3 570.0 1,318.7 1,189.8
Operating income 84.8 97.6 160.8 144.0
Interest expense, net (51.5) (47.7) (98.8) (94.5)
Income before income taxes 33.3 49.9 62.0 49.5
Income tax (expense) benefit (4.9) 7.8 (9.3) 9.4
Net income 28.4 57.7 52.7 58.9
Less: Net income attributable to non-controlling interests (43.9) (38.8) (80.6) (64.9)
Net (loss) income attributable to Surgery Partners, Inc. $ (15.5) $ 18.9 $ (27.9) $ (6.0)
Net (loss) income per share attributable to common stockholders:        
Basic (in USD per share) $ (0.12) $ 0.15 $ (0.22) $ (0.05)
Diluted (in USD per share) [1] $ (0.12) $ 0.15 $ (0.22) $ (0.05)
Weighted average common shares outstanding:        
Basic (shares) 126,134 125,718 126,053 125,463
Diluted (shares) [1] 126,134 127,370 126,053 125,463
[1] The impact of potentially dilutive securities for the three months ended June 30, 2024 and the six months ended June 30, 2024 and 2023 was not considered because the effect would be anti-dilutive.